Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Stock Information for Aditxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aditxt Inc.

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.